37 results about "Obesity associated disorder" patented technology

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

The invention discloses a bacterial strain as well as a composition and application, and relates to the technical field of strain separation and application. The Cristinia sp. provided by the invention can be applied to treatment or prevention of liver function impairment and liver function impairment related diseases, alimentary canal mucosal injury and alimentary canal mucosal injury related diseases, diabetes, obesity and obesity related diseases. The inventor verifies that the Cristinia sp. provided by the invention has no toxic or side effect on the kidney and can reduce the weight of the liver; the initial steatohepatitis focus can be treated; fat accumulation of liver cells can be slowed down; AST and ALT in serum can be reduced; and abdominal white fat inflammatory lesion can be reduced. The Cristinia sp. can also repair the digestive tract mucosa, recover the barrier function of the mucosa, and prevent and treat intestinal leakage, peptic ulcer and other diseases caused by barrier function impairment. The Cristinia sp. also has the effects of reducing fasting blood-glucose of a body, regulating insulin level and reducing body fat of mammals, and has the effects of preventing and treating diabetes and improving the metabolic function of obese patients.

The invention discloses a combined medicine containing microorganisms and a hypoglycemic and lipid-lowering medicine, and relates to the technical field of strain separation and application. The combined medicine containing the microorganisms and the blood glucose and lipid lowering medicine can be applied to treatment or prevention of liver function impairment, liver function impairment related diseases, diabetes mellitus, obesity and obesity related diseases. The inventor verifies that the combined medicine containing the microorganisms and the hypoglycemic and lipid-lowering medicine has the technical effect of synergistic interaction, the combined medicine has the treatment effect better than that of the single application of the microorganisms or the single application of the hypoglycemic and lipid-lowering medicine, and the microorganisms can enhance the weight losing effect of the hypoglycemic and lipid-lowering medicine, improve abnormal glucose tolerance and reduce fasting blood glucose. In addition, the combined medicine has no toxic or side effect on the kidney and can reduce the weight of the liver.

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of XOBESIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875.

The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.

Polypeptides and proteins that include a fragment of a ClpB protein and compositions therefrom. Methods of treatment and/or prevention of inflammation, in particular overweight and/or obesity-related diseases and disorders, with the polypeptides and proteins. Also, methods of inducing satiation, prolonging satiety, reducing meal size, reducing food intake, controlling weight gain and stimulating weight loss with the polypeptides and proteins.

The invention discloses a protein clusterin-clusterin related to obesity-related diseases, and a coding gene CLU (Clusterin) of the protein. The invention further discloses application of the protein clusterin related to the obesity-related diseases and the coding gene of the protein clusterin in preparation of drugs for preventing and treating the obesity-related diseases or kits for detecting the obesity-related diseases. The invention provides a gene or protein cluster related to obesity, and provides a theoretical basis and a new drug target for research and development of obesity drugs.

The present invention more particularly discloses the identification of human obesity susceptibility genes, which can be used for the diagnosis, prevention and treatment of obesity ant associated disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses certain alleles of potassium voltage-gated channel (E.CNA) genes related to susceptibility to obesity and representing novel targets for therapeutic intervention. More particularly, the potassium volt-age-gated channel (KCNA) genes are located on chromosome 12 and are selected from the group consisting of KCNA1, KCNA5 and KCNA6. The present invention relates to particular mutations in the KCNA1, KCNA5 and KCNA6 genes and their expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including but not limited to hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and associated complications and dyslipidemia.